Darolutamide linked to fewer hospitalizations in patients with mHSPC
January 25th 2024Compared with placebo, darolutamide was associated with a numerically lower rate of hospitalizations when combined with androgen-deprivation therapy and docetaxel to treat patients with metastatic hormone-sensitive prostate cancer.